Sanofi and DBV Technologies have entered a strategic manufacturing agreement under which Sanofi will produce the API for DBV’s Viaskin. Sanofi will provide scale-up, process validation, and commercial scale supply.
 
DBV selected Sanofi for its expertise in biologics development and manufacturing in the field of plant extraction and purification of therapeutic proteins. Also, Sanofi’s manufacturing site in Aramon, France, has all the necessary capabilities to support the registration of Viaskin for both the EU and U.S. markets.
 
Dr. Pierre-Henri Benhamou, chairman and chief executive officer of DBV Technologies, said, “The strategic manufacturing agreement with Sanofi is an important step for DBV in the light of Viaskin’s late-stage development and potentially fast-coming commercialization. We believe that the extraction and protein expertise of Sanofi, notably at the Aramon site, will highly benefit DBV, thereby securing our API procurement in the years to come. We were very impressed by the quality and reactiveness of the Sanofi teams, which match perfectly with DBV’s culture and look forward to working closely with them in the months to come.”